News Article | May 25, 2017
-- Spirax Sarco USA, the leader in products and services for steam systems, is teaming up with Spirax Sarco Canada to show support for the Enbridge® Ride to Conquer Cancer®. During one amazing weekend, June 10-11, 2017, they will cycle 200 kilometers with thousands of other men and women throughout the countryside of Toronto and Niagara to make a difference in the fight to conquer cancer worldwide. All net proceeds will benefit Princess Margaret Cancer Centre, a leader in this critical cause.There is little doubt that the time for action is now. According to the American Cancer Society in 2017, an estimated 1,688,780 new cancer cases are expected to be diagnosed in the United States, and 600,920 are expected to die of cancer.Lorraine Wiseman, President and General Manager of Spirax Sarco, states, "Cancer remains the second leading cause of death in our country, claiming more than half a million lives each year. That is one life lost to cancer every minute! The lifetime risk of developing cancer is as high as one in two for men, and one in three for women. I have financially supported this ride over the past four years and now would like to invite you to join me and the Spirax Sarco Teams and help cancer patients all over the world."Princess Margaret Cancer Centre is one of the world's top 5 cancer centers and is a leader in Personalized Cancer Medicine. Personalized Cancer Medicine is a multi-faceted, integrated approach to cancer care that focuses on the unique nature of each patient. Because every patient is unique, every patient's cancer is different. Funds raised through The Ride are enabling the researchers, scientists and doctors at Princess Margaret Cancer Centre to better understand the unique genes of each cancer and each patient, which are leading to more effective, targeted and less toxic treatments for cancer patients in Ontario and around the world. The Princess Margaret Cancer Foundation is ranked 2nd globally for cancer research and is the only non-American research facility that is granted research funding from the US National Cancer Institute. It is leading the world in clinical trials.This event will be an incredible, inspiring experience for everyone involved. Please help us make a difference and participate in this life changing experience. To donate or request information about The Ride, visit us atAbout Spirax Sarco, Inc.For engineers around the world, Spirax Sarco is synonymous with excellence in steam system management. We offer the industry's most extensive range of products and services, coupled with expertise based on over a century of practical application across a variety of industries. In short, we create the solutions that set the benchmark for steam-using organizations worldwide, working alongside them to improve productivity, save energy and reduce waste.Our commitment to customers is supported by over 1,100 dedicated engineers, a direct sales force in 55 countries worldwide, through which we serve customers in around 100 countries and complemented by substantial investment in state-of-the-art locally based manufacturing. Our aim is to help customers build a sustainable and profitable business, using their country and industry insight to tailor solutions precisely to their needs. Further information can be found at http://www.spiraxsarco.com/ global/us About The Princess MargaretPrincess Margaret Hospital and its research arm, the Ontario Cancer Institute, which includes The Campbell Family Cancer Research Institute and The Campbell Family Breast Cancer Research Institute, have achieved an international reputation as one of the top 5 cancer research centres in the world. Princess Margaret Hospital is a member of University Health Network which also includes Toronto General Hospital and Toronto Western Hospital. All three are research hospitals affiliated with the University of Toronto and more information about UHN can be found at www.uhn.ca.About The Princess Margaret Hospital FoundationThe Princess Margaret Hospital Foundation at University Health Network raises funds for research, exemplary teaching and compassionate care at Princess Margaret Hospital and its research arm, the Ontario Cancer Institute, which includes The Campbell Family Cancer Research Institute and The Campbell Family Cancer Institute. More information about the Foundation can be found at www.pmhf.ca.
Greenwood C.M.T.,McGill University |
Paterson A.D.,The Hospital for Sick Children |
Paterson A.D.,University of Toronto |
Linton L.,The Campbell Family Cancer Research Institute |
And 18 more authors.
Breast Cancer Research | Year: 2011
Introduction: Mammographic breast density is a highly heritable (h 2> 0.6) and strong risk factor for breast cancer. We conducted a genome-wide linkage study to identify loci influencing mammographic breast density (MD).Methods: Epidemiological data were assembled on 1,415 families from the Australia, Northern California and Ontario sites of the Breast Cancer Family Registry, and additional families recruited in Australia and Ontario. Families consisted of sister pairs with age-matched mammograms and data on factors known to influence MD. Single nucleotide polymorphism (SNP) genotyping was performed on 3,952 individuals using the Illumina Infinium 6K linkage panel.Results: Using a variance components method, genome-wide linkage analysis was performed using quantitative traits obtained by adjusting MD measurements for known covariates. Our primary trait was formed by fitting a linear model to the square root of the percentage of the breast area that was dense (PMD), adjusting for age at mammogram, number of live births, menopausal status, weight, height, weight squared, and menopausal hormone therapy. The maximum logarithm of odds (LOD) score from the genome-wide scan was on chromosome 7p14.1-p13 (LOD = 2.69; 63.5 cM) for covariate-adjusted PMD, with a 1-LOD interval spanning 8.6 cM. A similar signal was seen for the covariate adjusted area of the breast that was dense (DA) phenotype. Simulations showed that the complete sample had adequate power to detect LOD scores of 3 or 3.5 for a locus accounting for 20% of phenotypic variance. A modest peak initially seen on chromosome 7q32.3-q34 increased in strength when only the 513 families with at least two sisters below 50 years of age were included in the analysis (LOD 3.2; 140.7 cM, 1-LOD interval spanning 9.6 cM). In a subgroup analysis, we also found a LOD score of 3.3 for DA phenotype on chromosome 12.11.22-q13.11 (60.8 cM, 1-LOD interval spanning 9.3 cM), overlapping a region identified in a previous study.Conclusions: The suggestive peaks and the larger linkage signal seen in the subset of pedigrees with younger participants highlight regions of interest for further study to identify genes that determine MD, with the goal of understanding mammographic density and its involvement in susceptibility to breast cancer. © 2011 Greenwood et al.; licensee BioMed Central Ltd.
PubMed | The Campbell Family Cancer Research Institute
Type: Journal Article | Journal: Nature reviews. Cancer | Year: 2011
Interest in the topic of tumour metabolism has waxed and waned over the past century of cancer research. The early observations of Warburg and his contemporaries established that there are fundamental differences in the central metabolic pathways operating in malignant tissue. However, the initial hypotheses that were based on these observations proved inadequate to explain tumorigenesis, and the oncogene revolution pushed tumour metabolism to the margins of cancer research. In recent years, interest has been renewed as it has become clear that many of the signalling pathways that are affected by genetic mutations and the tumour microenvironment have a profound effect on core metabolism, making this topic once again one of the most intense areas of research in cancer biology.